DESIGN THERAPEUTICS INC (DSGN)
US25056L1035 - Common Stock
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024
DSGN stock results show that Design Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Design Therapeutics (NASDAQ:DSGN) just reported results for the first quarter o...
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal...
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious...
Wednesday 3/27 Insider Buying Report: SNPS, DSGN
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023
DSGN stock results show that Design Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Design Therapeutics (NASDAQ:DSGN) just reported results for the fourth quarter ...
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by...
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious...
Commit To Purchase Design Therapeutics At $2.50, Earn 26.4% Annualized Using Options
Biogen gets EU approval for Friedrich's ataxia drug (NASDAQ:BIIB)
Biogen (BIIB) said it has received EU approval for its drug Skyclarys for the treatment of Friedreich’s ataxia, or FA, in patients aged 16 years and older. Read more here.
Commit To Purchase Design Therapeutics At $2.50, Earn 28.8% Annualized Using Options
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such...
Tuesday 10/3 Insider Buying Report: DSGN, SPG
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such...
Why Shares of Design Therapeutics Are Plummeting on Tuesday
The biotech company released phase 1 trial details regarding a Friedreich ataxia therapy.
RBC Capital cuts Design Therapeutics to sector perform, cites limited catalysts (DSGN)
RBC Capital has downgraded Design Therapeutics (DSGN) to sector perform, citing limited near-term catalysts as its reformulates its lead drug candidate DT-216. Read more here.